![\"z-cristin-vincristine\"](\"https:\/\/i0.wp.com\/www.zuviuslifesciences.in\/media\/124281\/z-cristin-vincristine-desc.jpg?resize=528%2C461&ssl=1\")
<\/p>\n
Vincristine Sulfate, USP is a white to off\u2013white powder. It is soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol. In 98% ethanol, Vincristine Sulfate, USP has an ultraviolet spectrum with maxima at 221 nm (\u2208+47,100).<\/p>\n
Vincristine Sulfate Injection, USP is a sterile, preservative\u2013free, single use only solution available for intravenous use in 2 mL (1 mg and 2 mg) vials. Each mL contains 1 mg Vincristine Sulfate, USP, 100 mg mannitol and Water for Injection, USP. Q.S. Sulfuric acid or sodium hydroxide have been added for pH control. The pH of Vincristine Sulfate Injection, USP ranges from 4.0 to 5.0. At the time of manufacture, the air in the containers is replaced by nitrogen.<\/p>\n
Chemically Oxaliplatin is trans -I \u2013 diaminocyclothexane oxatatoplatinum or cis \u2013(oxalate(trans \u2013(1.2, -diamino-cyclothexane) platinum (III) . The empirical formula of Oxaliplatin is C\u2082H4 N2 O4 Pt. The molecular weight of Oxaliplatin is 397.30. Oxaliplatin is slightly soluble in water and methanol , and insoluble in ehanol.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Composition” tab_id=”1593176233963-75c1cb47-fa3b”][vc_column_text]GENERIC NAME:<\/strong>\u00a0VINCRISTINE SULPHATE<\/p>\n Each Vial Contains:<\/p>\n Vincristine Sulphate IP equivalent to Vincristin\u2026\u2026\u2026\u2026..1mg<\/p>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Mechanism of Action \/ Pharmcodynamics” tab_id=”1584624217050-ebb8ae5e-43a6″][vc_column_text]The mechanisms of action of vincristine sulfate remain under investigation. The mechanism of action of vincristine sulfate has been related to the inhibition of microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage.<\/p>\n Central nervous system leukemia has been reported in patients undergoing otherwise successful therapy with vincristine sulfate. This suggests that vincristine does not penetrate well into the cerebrospinal fluid.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Pharmacokinetics” tab_id=”1584624459062-96fb7e5b-0e23″][vc_column_text]Pharmacokinetic studies in patients with cancer have shown a triphasic serum decay pattern following rapid intravenous injection. The initial, middle and terminal half\u2013lives are 5 minutes, 2.3 hours, and 85 hours respectively; however, the range of the terminal half\u2013life in humans is from 19 to 155 hours. The liver is the major excretory organ in humans and animals. The metabolism of vinca alkaloids has been shown to be mediated by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily. This metabolic pathway may be impaired in patients with hepatic dysfunction or who are taking concomitant potent inhibitors of these isoenzymes About 80% of an injected dose of vincristine sulfate appears in the feces and 10% to 20% can be found in the urine. Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.<\/p>\n Current principles of cancer chemotherapy involve the simultaneous use of several agents. Generally, each agent used has a unique toxicity and mechanism of action so that therapeutic enhancement occurs without additive toxicity. It is rarely possible to achieve equally good results with single\u2013agent methods of treatment. Thus, vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone\u2013marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Indications” tab_id=”1584624839401-59481bbb-bdc7″][vc_column_text]Vincristine sulfate injection is indicated in acute leukemia.<\/p>\n Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin\u2019s disease, non\u2013Hodgkin\u2019s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms\u2019 tumor.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Dosage & Administration” tab_id=”1584625017135-3ffdd9c5-1bd6″][vc_column_text]This preparation is for intravenous use only.<\/p>\n Neurotoxicity appears to be dose related. Extreme care must be used in calculating and administering the dose of \u00a0Vincristine Sulfate Injection, USP<\/strong>\u00a0\u00a0 since overdosage may have a very serious or fatal outcome.<\/p>\n The usual dose of Vincristine Sulfate Injection, USP for pediatric patients is 1.5\u20132 mg\/m2 . For pediatric patients weighing 10 kg or less, the starting dose should be 0.05 mg\/kg, administered once a week. The usual dose of Vincristine Sulfate Injection, USP for adults is 1.4 mg\/m2 . A 50% reduction in the dose of Vincristine Sulfate Injection, USP is recommended for patients having a direct serum bilirubin value above 3 mg\/100 mL.<\/p>\n The drug is administered intravenously \u00a0at weekly intervals.<\/p>\n TO REDUCE THE POTENTIAL FOR FATAL MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION, VINCRISTINE SULFATE INJECTION SHOULD BE DILUTED IN A FLEXIBLE PLASTIC CONTAINER AND PROMINENTLY LABELED FOR INTRAVENOUS USE ONLY.<\/strong><\/p>\n The concentration of Vincristine Sulfate Injection, USP is 1 mg\/mL. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP into an accurate dry syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.<\/p>\n Preparation for flexible plastic container<\/strong><\/p>\n Vincristine Sulfate Injection, USP when diluted with 0.9% Sodium Chloride Injection in concentrations from 0.0015 mg\/mL to 0.08 mg\/mL is stable for up to 24 hours when protected from light or 8 hours under normal light at 25\u00b0C.<\/p>\n Preparation for syringe :<\/strong><\/p>\n Special Dispensing Information:<\/strong>\u00a0when dispensing Vincristine Sulfate Injection, USP in a syringe, it is imperative that it be packaged in the provided overwrap which bears the following statement: \u00a0\u201cDO NOT REMOVE COVERING UNTIL MOMENT OF INJECTION. FOR INTRAVENOUS USE ONLY \u2013 FATAL IF GIVEN BY OTHER ROUTES\u201d<\/strong>\u00a0A syringe containing a specific dose must be labeled, using the auxiliary sticker provided, to state: \u00a0\u201cFOR INTRAVENOUS USE ONLY\u00a0<\/strong>– FATAL IF GIVEN \u00a0BY OTHER ROUTES.\u201d<\/p>\n Caution: It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissue during intravenous administration of Vincristine Sulfate Injection, USP may cause considerable irritation.<\/strong>\u00a0\u00a0 If extravasation occurs, the injection should be discontinued immediately and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage will help disperse the drug and may minimize discomfort and the possibility of cellulitis.<\/p>\n Vincristine Sulfate Injection, USP must be administered via an intact, free\u2013flowing intravenous needle or catheter. Care should be taken that there is no leakage or swelling occurring during administration.<\/p>\n The solution may be injected either directly into a vein or into the tubing of a running intravenous infusion (see \u00a0Drug Interactions<\/strong>\u00a0below). Injection of Vincristine Sulfate Injection, USP should be accomplished within 1 minute.<\/p>\n Patients Receiving Radiation Therapy<\/strong>\u00a0– Vincristine Sulfate Injection, USP should not be given to patients while they are receiving radiation therapy through ports that include the liver. When Vincristine Sulfate Injection, USP is used in combination with L\u2013asparaginase, Vincristine Sulfate Injection, USP should be given 12 to 24 hours before administration of the enzyme in order to minimize toxicity; administering L\u2013asparaginase before Vincristine Sulfate Injection, USP may reduce hepatic clearance of vincristine.<\/p>\n Handling and Disposal \u2013<\/strong>Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Warnings” tab_id=”1587978464677-818e3c8a-8b36″][vc_column_text]<\/p>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Precautions” tab_id=”1587978466341-e08f7517-4cca”][vc_column_text]<\/p>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Adverse Reactions (Side Effects)” tab_id=”1587978467943-190d6254-3b32″][vc_column_text]Prior to the use of this drug, patients \u00a0and\/or their parents\/guardian should be advised of the possibility of untoward \u00a0symptoms.<\/p>\n In general, adverse reactions are reversible and are related to \u00a0dosage. The most common adverse reaction is hair loss; the most troublesome \u00a0adverse reactions are neuromuscular in origin.<\/p>\n When single, weekly doses of the drug are employed, the adverse \u00a0reactions of leukopenia, neuritic pain, and constipation occur but are usually \u00a0of short duration (ie., less than 7 days). When the dosage is reduced, these \u00a0reactions may lessen or disappear. The severity of such reactions seems to \u00a0increase when the calculated amount of drug is given in divided doses. Other \u00a0adverse reactions, such as hair loss, sensory loss, paresthesia, difficulty in \u00a0walking, slapping gait, loss of deep\u2013tendon reflexes, and muscle wasting, may \u00a0persist for at least as long as therapy is continued. Generalized sensorimotor \u00a0dysfunction may become progressively more severe with continued treatment. \u00a0Although most such symptoms usually disappear by about the sixth week after \u00a0discontinuance of treatment, some neuromuscular difficulties may persist for \u00a0prolonged periods in some patients. Regrowth of hair may occur while \u00a0maintenance therapy continues.<\/p>\n The following adverse reactions have been reported:<\/strong><\/p>\n Hepatic veno-occlusive disease has been reported in patients \u00a0receiving vincristine, particularly in pediatric patients, as part of standard \u00a0combination chemotherapy regimens. Some of the patients had fatal outcomes; \u00a0some who survived had undergone liver transplantation.<\/p>\n Hypersensitivity \u2013<\/strong>Rare cases of \u00a0allergic\u2013type reactions, such as anaphylaxis, rash and edema, that are \u00a0temporally related to vincristine therapy have been reported in patients \u00a0receiving vincristine as a part of multidrug chemotherapy regimens.<\/p>\n Gastrointestinal \u2013<\/strong>Constipation, abdominal \u00a0cramps, weight loss, nausea, vomiting, oral ulceration, diarrhea, paralytic \u00a0ileus, intestinal necrosis and\/or perforation, and anorexia have occurred. \u00a0Constipation may take the form of upper\u2013colon impaction, and, on physical \u00a0examination, the rectum may be empty. Colicky abdominal pain coupled with an \u00a0empty rectum may mislead the physician. A flat film of the abdomen is useful in \u00a0demonstrating this condition. All cases have responded to high enemas and \u00a0laxatives. A routine prophylactic regimen against constipation is recommended \u00a0for all patients receiving vincristine sulfate injection.<\/p>\n Paralytic ileus (which mimics the \u201csurgical abdomen\u201d) may occur, \u00a0particularly in young pediatric patients. The ileus will reverse itself with \u00a0temporary discontinuance of vincristine sulfate injection and with symptomatic \u00a0care.<\/p>\n Genitourinary \u2013<\/strong>Polyuria, dysuria, and \u00a0urinary retention due to bladder atony have occurred. Other drugs known to \u00a0cause urinary retention (particularly in the elderly) should, if possible, be \u00a0discontinued for the first few days following administration of vincristine \u00a0sulfate injection.<\/p>\n Cardiovascular \u2013<\/strong>Hypertension and \u00a0hypotension have occurred. Chemotherapy combinations that have included \u00a0vincristine sulfate, when given to patients previously treated with mediastinal \u00a0radiation, have been associated with coronary artery disease and myocardial \u00a0infarction. Causality has not been established.<\/p>\n Neurologic \u2013<\/strong>Frequently, there is a \u00a0sequence to the development of neuromuscular side effects. Initially, only \u00a0sensory impairment and paresthesia may be encountered. With continued \u00a0treatment, neuritic pain and, later, motor difficulties may occur. There have \u00a0been no reports of any agent that can reverse the neuromuscular manifestations \u00a0that may accompany therapy with vincristine sulfate.<\/p>\n Loss of deep\u2013tendon reflexes, foot drop, ataxia, and paralysis \u00a0have been reported with continued administration. Cranial nerve manifestations, \u00a0such as isolated paresis and\/or paralysis of muscles controlled by cranial \u00a0motor nerves including potentially life\u2013threatening bilateral vocal cord paralysis, \u00a0may occur in the absence of motor impairment elsewhere; extraocular and \u00a0laryngeal muscles are those most commonly involved. Jaw pain, pharyngeal pain, \u00a0parotid gland pain, bone pain, back pain, limb pain, and myalgias have been \u00a0reported; pain in these areas may be severe. Convulsions, frequently with \u00a0hypertension, have been reported in a few patients receiving vincristine \u00a0sulfate. Several instances of convulsions followed by coma have been reported \u00a0in pediatric patients. Transient cortical blindness and optic atrophy with \u00a0blindness have been reported. Treatment with vinca alkaloids has resulted in \u00a0both vestibular and auditory damage to the eighth cranial nerve. Manifestations \u00a0include partial or total deafness which may be temporary or permanent, and \u00a0difficulties with balance including dizziness, nystagmus, and vertigo. \u00a0Particular caution is warranted when vincristine is used in combination with \u00a0other agents known to be ototoxic such as the platinum\u2013containing oncolytics.<\/p>\n Endocrine \u2013<\/strong>Rare occurrences of a \u00a0syndrome attributable to inappropriate antidiuretic hormone secretion have been \u00a0observed in patients treated with vincristine sulfate. This syndrome is \u00a0characterized by high urinary sodium excretion in the presence of hyponatremia; \u00a0renal or adrenal disease, hypotension, dehydration, azotemia, and clinical \u00a0edema are absent. With fluid deprivation, improvement occurs in the \u00a0hyponatremia and in the renal loss of sodium.<\/p>\n Hematologic \u2013<\/strong>Vincristine sulfate \u00a0injection does not appear to have any constant or significant effect on \u00a0platelets or red blood cells. Serious bone\u2013marrow depression is usually not a \u00a0major dose\u2013limiting event. However, anemia, leukopenia, and thrombocytopenia \u00a0have been reported. Thrombocytopenia, if present when therapy with vincristine sulfate \u00a0injection is begun, may actually improve before the appearance of bone marrow \u00a0remission.<\/p>\n Skin \u2013<\/strong>Alopecia and rash have \u00a0been reported.<\/p>\n Other \u2013<\/strong>Fever and headache have \u00a0occurred.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Drug Interactions” tab_id=”1587978788920-a652582e-1377″][vc_column_text]Vincristine Sulfate Injection, USP should not be diluted in solutions that raise or lower the pH outside the range of 3.5 to 5.5. It should not be mixed with anything other than normal saline or glucose in water.<\/p>\n Whenever solution and container permit, parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Overdose & Contradiction” tab_id=”1587978790937-0b0c9a9f-418f”][vc_column_text]Side effects following the use of vincristine sulfate \u00a0injection are dose related. In pediatric patients under 13\u00a0years of age, \u00a0death has occurred following doses of vincristine sulfate that were 10 times \u00a0those recommended for therapy. Severe symptoms may occur in this patient group \u00a0following dosages of 3\u00a0to\u00a04\u00a0mg\/m2. Adults can be \u00a0expected to experience severe symptoms after single doses of 3\u00a0mg\/m2or more (see ADVERSE REACTIONS above). Therefore, following administration of doses higher \u00a0than those recommended, patients can be expected to experience exaggerated side \u00a0effects. Supportive care should include the following: (1) prevention of side \u00a0effects resulting from the syndrome of inappropriate antidiuretic hormone \u00a0secretion (preventive treatment would include restriction of fluid intake and \u00a0perhaps the administration of a diuretic affecting the function of Henle\u2019s loop \u00a0and the distal tubule); (2) administration of anticonvulsants; (3) use of \u00a0enemas or cathartics to prevent ileus (in some instances, decompression of the \u00a0gastrointestinal tract may be necessary); (4) monitoring the cardiovascular \u00a0system; (5) determining daily blood counts for guidance in transfusion \u00a0requirements.<\/p>\n Folinic acid has been observed to have a protective effect \u00a0in normal mice that were administered lethal doses of vincristine sulfate (Cancer Res\u00a01963;23:1390). Isolated case reports \u00a0suggest that folinic acid may be helpful in treating humans who have received \u00a0an overdose of vincristine sulfate. It is suggested that 100 mg of folinic acid \u00a0be administered intravenously every 3 hours for 24 hours and then every 6 hours \u00a0for at least 48 hours. Theoretically (based on pharmacokinetic data), tissue \u00a0levels of vincristine sulfate can be expected to remain significantly elevated \u00a0for at least 72 hours. Treatment with folinic acid does not eliminate the need \u00a0for the above mentioned supportive measures.<\/p>\n Most of an intravenous dose of vincristine is excreted \u00a0into the bile after rapid tissue binding ). Because only very small amounts of the drug appear in \u00a0dialysate, hemodialysis is not likely to be helpful in cases of overdosage. An \u00a0increase in the severity of side effects may be experienced by patients with \u00a0liver disease that is severe enough to decrease biliary excretion.<\/p>\n Enhanced fecal excretion of parenterally administered \u00a0vincristine has been demonstrated in dogs pretreated with cholestyramine. There \u00a0are no published clinical data on the use of cholestyramine as an antidote in \u00a0humans.<\/p>\n There are no published clinical data on the consequences of oral \u00a0ingestion of vincristine. Should oral ingestion occur, the stomach should be \u00a0evacuated. Evacuation should be followed by oral administration of activated \u00a0charcoal and a cathartic.<\/p>\n Treatment of patients following intrathecal administration \u00a0of vincristine sulfate injection has included immediate removal of spinal fluid \u00a0and flushing with Lactated Ringer\u2019s, as well as other solutions and has not \u00a0prevented ascending paralysis and death. In one case, progressive paralysis in \u00a0an adult was arrested by the following treatment\u00a0initiated immediately after the intrathecal injection:<\/strong><\/p>\n CONTRADICATIONS<\/strong><\/p>\n Patients with the demyelinating form of Charcot\u2013Marie\u2013Tooth syndrome should not be given vincristine sulfate injection.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Storage” tab_id=”1587978793604-7c71901c-62cf”][vc_column_text]This product should be refrigerated between 2\u00b0\u20138\u00b0C (36\u00b0\u201346\u00b0F). Discard unused solution. Protect from light. Store Upright.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Presentation” tab_id=”1587978938510-bff2f998-3197″][vc_column_text]Vincristine Sulfate Injection, USP, preservative free solution.<\/p>\n 1 mg\/1 mL (single use)<\/p>\n 2 mg\/2 mL (single use)[\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":" Vincristine sulfate injection is indicated in acute leukemia.<\/p>\n Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin\u2019s disease, non\u2013Hodgkin\u2019s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms\u2019 tumor.<\/p>\n","protected":false},"featured_media":6744,"template":"","meta":{"spay_email":""},"product_cat":[66,68],"product_tag":[175,174],"jetpack-related-posts":[{"id":6701,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/z-blastin-inj\/","url_meta":{"origin":6743,"position":0},"title":"Z-Blastin Inj","date":"April 26, 2020","format":false,"excerpt":"Vinblastine Inj - 10MG \u00a0","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/image-10-3.jpg?fit=615%2C385&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6717,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zolon-inj\/","url_meta":{"origin":6743,"position":1},"title":"Zolon Inj","date":"April 27, 2020","format":false,"excerpt":"Oxaliplatin Inj - 150MG 100MG 50MG Oxaliplatin is indicated in the treatment of metastatic colorectal cancers after the failure of treatment of fluoropyrimidines, alone by monochemotherapy or along with fluoropyrimidines. \u00a0","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zolon-Group-2_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6696,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zuvitop-inj\/","url_meta":{"origin":6743,"position":2},"title":"Zuvitop Inj","date":"April 25, 2020","format":false,"excerpt":"\u00a0Etoposide\u00a0 Inj -\u00a0 100MG Etoposide Injection is indicated in the management of the following neoplasms. Small cell lung cancer, \u00a0malignant lymphomas Acute leukemia\u2019s... Testicular tumors. Bladder Cancer. Trophoblastic \u00a0diseases Etoposide Injection are indicated in the management of the following neoplasms. Small cell lung cancer. \u00a0Malignant lymphomas.","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zuvitop-Group_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":7617,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/aspraginaz-inj\/","url_meta":{"origin":6743,"position":3},"title":"Aspraginaz Inj","date":"July 15, 2020","format":false,"excerpt":"ASPRAGINAZ (L-Asparaginase) is indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. ASPRAGINAZ (L-Asparaginase) should not be used as the sole induction agent unless combination therapy is\u2026","rel":"","context":"Similar post","img":{"alt_text":"Aspraginaz_3_1000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/07\/Aspraginaz_3_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6727,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/bleoz-inj\/","url_meta":{"origin":6743,"position":4},"title":"Bleoz Inj","date":"April 27, 2020","format":false,"excerpt":"Bleomycin Inj IP -15 units, 30 units BLEOZ should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents. Squamous cell Carcinoma Head and neck (including mouth,\u2026","rel":"","context":"Similar post","img":{"alt_text":"Bleoz 1mg_1_1000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Bleoz-1mg_1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6689,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/dazine-inj\/","url_meta":{"origin":6743,"position":5},"title":"Dazine Inj","date":"April 25, 2020","format":false,"excerpt":"Dacarbazine Inj - 200 MG, 500MG Dazine is indicated in the treatment of metastatic malignant melanoma, Hodgkin' disease as a secondary-line therapy when used in combination with other effective agents, neuroblastoma, soft-tissue sarcoma including leiomyosarcoma","rel":"","context":"Similar post","img":{"alt_text":"Dazine 200mg & 500mg_3_000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Dazine-200mg-500mg_3_000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product\/6743"}],"collection":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/media\/6744"}],"wp:attachment":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/media?parent=6743"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product_cat?post=6743"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product_tag?post=6743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
Vincristine Inj – 1MG<\/h3>\n